Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA382990
Max Phase: Preclinical
Molecular Formula: C30H38N4O6
Molecular Weight: 550.66
Molecule Type: Small molecule
Associated Items:
ID: ALA382990
Max Phase: Preclinical
Molecular Formula: C30H38N4O6
Molecular Weight: 550.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)NCc2ccccc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1
Standard InChI: InChI=1S/C30H38N4O6/c1-5-6-17-23(24(35)26(36)32-20(2)22-15-11-8-12-16-22)33-29(39)40-25-27(37)34(19-30(25,3)4)28(38)31-18-21-13-9-7-10-14-21/h7-16,20,23,25H,5-6,17-19H2,1-4H3,(H,31,38)(H,32,36)(H,33,39)/t20-,23+,25-/m1/s1
Standard InChI Key: DEAALBPCNSJIPH-JHMXWDHMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 550.66 | Molecular Weight (Monoisotopic): 550.2791 | AlogP: 3.86 | #Rotatable Bonds: 11 |
Polar Surface Area: 133.91 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.24 | CX Basic pKa: | CX LogP: 4.69 | CX LogD: 4.69 |
Aromatic Rings: 2 | Heavy Atoms: 40 | QED Weighted: 0.36 | Np Likeness Score: -0.36 |
1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.. (2006) Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors., 16 (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101] |
Source(1):